Barriers to growth for novel CKD-MBD treatments viewed by analyst

Even though the chronic kidney disease–mineral bone disorder (CKD-MBD) market is set to face several barriers to growth over the next decade, the anticipated launch of US drugmaker Ardelyx’ (Nasdaq: ARDX) tenapanor in the US market in 2020 may be an answer to the growing demand for novel CKD-MBD treatments, says data and analytics company.

CKD-MBD is an umbrella term used to link renal osteodystrophy with mineral bone disorders and bone pathology associated with CKD. In 2017 alone, it was estimated that there were over 19 million diagnosed prevalent cases across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, Japan and China).

It is the second most investigated indication in the metabolic disorder therapy area across the markets. An analysis of data from GlobalData’s Pharma Intelligence Center reveals that CKD-MBD accounts for 7% of all genitourinary (including sex hormone therapy) clinical trials (n=330), with 112 completed clinical trials and 18 in planned/ongoing Phase II and Phase III interventional studies.